Acute disseminated encephalomyelitis (ADEM) is an inflammatory demyelinating disease of the central nervous system (CNS) characterised by encephalopathy and other neurological manifestations. ADEM is a heterogeneous syndrome predominantly found in the paediatric population. ADEM usually takes a monophasic course, but some patients have a relapsing disease. Patients diagnosed with ADEM have multifocal CNS lesions including of the spinal cord and/or optic nerves. Therefore, ADEM should be distinguished from other diseases such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD). Over the past years, several disease-specific autoantibodies such as aquaporin-4 (AQP4)-IgG in NMOSD have been discovered, revolutionising the understanding of underlying pathogenic mechanisms and identifying a broader clinical spectrum related to the disease, as seen in NMOSD. 1 However, antibodies against myelin oligodendrocyte glycoprotein (MOG) have been reported in some inflammatory CNS diseases and early assays using denatured protein (western blot) or linear peptides (ELISA) showed low specificity. The interest on MOG-IgG has risen again recently after the development of assays that can detect conformational sensitive antibodies in unique subgroups of patients with paediatric ADEM and NMOSD. 
